more_reports

Dr. Joseph Pantginis

H.C. Wainwright & Co.

Image: Dr. Joseph Pantginis

Joseph Pantginis, Ph.D., joined H.C. Wainwright as Managing Director covering Biotechnology. Dr. Pantginis has over 15 years of sell-side experience covering biotechnology companies, having spent most of those years at ROTH Capital Partners and Canaccord Adams. Prior to his sell-side career, he worked at Regeneron Pharmaceuticals, where he founded the Retrovirus Core Facility, providing molecular biology service and retroviral vectors to a broad range of Regeneron's research programs. His therapeutic focus is oncology, as well as regenerative medicine and gene therapy. He is also widely recognized for his expertise in cancer immunotherapy as a therapeutic approach to treating cancer. Dr. Pantginis received a B.S. in Biology from Fordham University, an M.B.A. in finance from Pace University, and a Ph.D. in Molecular Genetics from the Albert Einstein College of Medicine.

Recent Articles about Sernova Biotherapeutics Inc.

Biotech Requests OK to Assess Device in Second Indication 02/06/2025

The company behind this possible "pipeline in a device" wants to evaluate it now in thyroid disease after having begun with trials in type 1 diabetes, noted an H.C. Wainwright & Co. report.

Trial Data Help Position Cell Pouch for Commercial Success 09/16/2024

The upside implied in the target price on this Canadian firm, developing regenerative medicine platform technologies, is 1,900%, noted an H.C. Wainwright & Co. report.